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Abstract: Obesity is a worldwide epidemic responsible for 5% of global mortality. The risks of
developing other key metabolic disorders like diabetes, hypertension and cardiovascular diseases
(CVDs) are increased by obesity, causing a great public health concern. A series of epidemiological
studies and animal models have demonstrated a relationship between the importance of vitamin B12
(B12) and various components of metabolic syndrome. High prevalence of low B12 levels has been
shown in European (27%) and South Indian (32%) patients with type 2 diabetes (T2D). A longitudinal
prospective study in pregnant women has shown that low B12 status could independently predict
the development of T2D five years after delivery. Likewise, children born to mothers with low B12
levels may have excess fat accumulation which in turn can result in higher insulin resistance and
risk of T2D and/or CVD in adulthood. However, the independent role of B12 on lipid metabolism,
a key risk factor for cardiometabolic disorders, has not been explored to a larger extent. In this
review, we provide evidence from pre-clinical and clinical studies on the role of low B12 status on
lipid metabolism and insights on the possible epigenetic mechanisms including DNA methylation,
micro-RNA and histone modifications. Although, there are only a few association studies of B12
on epigenetic mechanisms, novel approaches to understand the functional changes caused by these
epigenetic markers are warranted.
Keywords: vitamin B12 (B12); lipid metabolism; cardiovascular disease (CVD); obesity; metabolic
syndrome (MetS); type 2 diabetes mellitus (T2D)
1. Introduction
Obesity is currently a worldwide epidemic that results in higher insulin resistance and increases
the risk of developing metabolic disorders like type 2 diabetes mellitus (T2D), hypertension and
cardiovascular diseases (CVDs) [1], thus, posing a critical public health concern [2]. Approximately
2.1 billion (30%) humans worldwide are reported to be obese or overweight, contributing to 5% of
global mortality. If sustained, the prevalence rate of obesity is likely to increase to 50% of the global
adult population by 2030 [3]. In addition, studies from the global hunger index have reported that,
approximately 2 billion people globally are affected by deficiency of micronutrients. The world health
organization (WHO) is specifically concerned about the levels of vitamin B12 (B12) and folate (B9) due
to increasing prevalence of their deficiencies across the populations [4]. Epidemiological studies have
also clearly shown the association of these nutritional metabolites and manifestations of metabolic
risk [5–8].
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Dyslipidemia is a key risk factor for atherosclerosis and CVD. Studies have also shown the
association of low B12 with obesity, hypertension, T2D and metabolic syndrome (MetS) in diverse
populations. Low B12 may also be associated with adverse lipid profile and CVDs [9]. In pre-clinical
studies, low B12 levels might increase lipid accumulation in adipocytes and trigger dyslipidemia in
mice [10], suggesting that low B12 and dyslipidemia might be causally related.
Obesity could be developed principally, as a result of excessive macronutrient intake and/or
reduced energy expenditure, which in-turn triggers disruption in lipid and glucose homeostasis.
However, the contribution of low levels of micronutrients, such as B12 to the pathogenesis of obesity
and dyslipidemia has not been fully explored. This review is aimed at summarizing the current
knowledge and latest evidence of the effect of low B12 on lipid metabolism, particularly the clinical
studies and epidemiological observations from pregnant women, adolescents, and adults. It will also
summarize the pre-clinical evidence from cell-lines, animal models and the possible molecular and
epigenetic mechanisms involved.
The current review has been produced following a detailed search of literature using the
MEDLINE/PubMed [11] and Global Health (CABI) [12] databases. Medical subject headings (MeSH)
and keywords such as “vitamin B12 deficiency”, “insufficiency of B12”, “vitamin B12” or “cobalamin”
were used. Combinations of these keywords with “pregnancy”, “vegetarians”, “lipid metabolism” and
“metabolic disorders” were achieved using Boolean operators (OR, AND).
2. B12: Biochemical Structure, Sources, Bioavailability, Cellular Uptake and Metabolism
B12 (cobalamin) is classified as an essential vitamin as it is entirely obtained from diet. It is also
synthesized naturally by some large intestine-resident bacteria in humans [13]. However, the site
of absorption in the small intestine is significantly distant from the site of synthesis, accounting for
non-bioavailability of the naturally synthesized B12 in humans [14,15]. B12 was first isolated in the year
1948 [16], following the discovery of using liver extract as a source of therapy for pernicious anemia [17].
Using x-ray crystallography, B12 was structurally described as a massive organometallic compound
with its size ranging between 1300 to 1500 Da [18]. The vitamin is uniquely composed of a central
cobalt atom linked to six ligands, with four of the latter structurally reduced to form a corrin ring that
connects and encircles the former through direct nitrogen linkages. Directly below the central cobalt is
an α-axial 5,6-dimethylbenzimidazole (DMB) ligand which, through a phosphoribosyl moiety, links to
the corrin ring and confers a high specificity on the vitamin for intrinsic factor (IF) binding in the lower
gastrointestinal tract [19]. The β-axial ligand (R-ligand), positioned above the corrin ring, may differ
in diverse forms such as methyl, 5′–deoxyadenosyl, hydroxo, acquo or cyano groups. These are,
therefore, named as methylcobalamin, deoxyadenosylcobalamin, hydroxycobalamin, acquocobalamin
and cyanocobalamin, respectively.
B12 is predominantly absent in plants, however, it is reported that traces of B12 could be obtained
in dried purple and green lavers and some edible algae [20]. Natural sources are predominately present
in animals and animal products such as meat, eggs and milk. The loss of fat and moisture associated
with cooking of beef has been reported to account for an average loss of 27–C33% B12 per unit nitrogen,
suggesting that extensive cooking might decrease the levels of B12 in food [21]. The bioavailability of
B12 in eggs is relatively lower (<9%) compared with other sources such as meats from chicken (61–66%),
sheep (56–89%) and fish (42%) [20]. It is also presumed that in healthy adults, with non-defective
gastrointestinal tract (GIT), the bioavailability of dietary B12 is about 50%. In addition, the GIT-resident
microorganisms possess the enzymes needed for B12 biosynthesis [22,23]. The absorptive capability of
the GIT of an individual undergoes adverse alteration with age, affecting the bioavailability of B12
in humans [24]. However, the absorption of B12, aided by availability of calcium, occurs at terminal
ileum where precise receptors (cubam) are expressed on the microvilli on the intestinal endothelium.
These receptors bind the IF-B12 complex followed by B12 delivery into the peripheral blood [24,25].
In humans, the plasma proteins transcobalamin (TC) and haptocorrin (HC) are proposed to be
crucial in the transport of B12 through circulation. TC, demonstrating a relatively increased selectivity
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for B12 in humans, forms a TC–B12 complex called holo-transcobalamin (holo-TC) which is reported
as the biologically active proportion of B12 within circulation [26]. The precise role of HCs in humans
is unclear, although they bind the greater proportion (80%) of circulating B12. HCs are reported to
express a relatively lower selectivity for B12, compared to TC, suggesting that they might either play a
role in the clearance of damaged forms of B12 or serve as B12 reservoirs in humans [26]. Generally,
within all body cells including hepatocytes (Figure 1), B12 is believed to undergo processing into
key cytosolic (MeCbl) and mitochondrial (AdoCbl) co-enzyme forms. A significant amount of the
biologically active water soluble B12 is believed to accumulate in the liver of healthy humans. In liver
biopsy samples from healthy humans, the average B12 content per gram of wet liver tissue is 1.94 µg
(range: 1.41 to 2.58 µg) [27]. It is reported, however, that B12 content of the human liver may be lower
in cases of cirrhosis, viral hepatitis, fatty liver and or obstructive jaundice [27]. Moreover, the human
body is known to eliminate a total of about 2 to 5 µg of B12 daily, primarily, via feces and minimal
amounts in urine [28].
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Figure 1. Cellular (hepatocyte) uptake and metabolism of vitamin B12 (B12): Cells generally internalize
B12-bound transcobolamin (holo-TC) with the aid of transcobalamin receptor (TCR) TCbIR/CD320
via endocytosis and fused into lysosomes. Within this organelle, B12 is liberated from the TC with
the latter (Apo-TC) subjected to degradation whilst the former (B12) is transported to the cytosol
and further processed to its catalytic forms, methyl-cobalamin (MeCbl) and 5′-adenosyl cobalamin
(AdoCbl), acting in the cytosol and mitochondria as co-enzymes in the methyl malonyl CoA utase
(MCM) and methionine synthase (MS) pathways, respectively. The transcobalamin receptors (TCbIR)
are however recycled back to the cellular surface membrane.
3. Vitamin B12 Deficiency: Diagnostic Markers and Risk Factors
There is no international consensus on the lower limit of B12 to define B12 deficiency in adults
and pregnancy. But there is some agreement that it should be between 120 and 220 pmol/L (higher
threshold in pregnancy) with the upper limit between 650 and 850 pmol/L [29]. Other parameters, such
as holo-TC, methyl malonic acid (MMA) and homocysteine (tHcy), are better markers of tissue level B12
deficiency, especially when the serum B12 levels are borderline (150–220 pmol/L) [5]. In the expanded
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newborn screening, estimation of metabolites such as propionylcarnitine, MMA and tHcy in samples
of newborn dry blood spot, using the tandem mass spectrometry, can facilitate the early diagnosis of
infant B12 deficiency resulting from maternal low B12 [30]. Since elevation of the metabolites MMA
and tHcy is associated with congenital disorders of B12 (as shown in Table 1), these also should be
considered in the differential diagnoses [31].
Currently, there is limited data on the prevalence of B12 deficiency globally, based on tHcy MMA
levels [32]. The risk of developing B12 deficiency is higher in vegetarian populations such as in
India [33]. However, it is not uncommon in other populations, ranging between 10 and 30% [29].
And is higher in pregnant populations [29]. Some of the causes of B12 deficiency are shown in Table 1.
Table 1. Causes of B12 deficiency [34].
(a) Reduced B12 Intake
i. Malnutrition
ii. Vegetarian diet
iii. Alcohol abuse
iv. Old age (>75 years)
(b) An Impairment of B12 Bioavailability Via Gastric Wall Damage (with a Decrease in Intrinsic Factor)
i. Total (in certain stomach cancers) or partial gastrectomy including bariatric surgery.
ii. Atrophic autoimmune gastritis (such as pernicious anemia) or other gastritis (e.g., Helicobactor pylori).
(c) Impairment of Absorption Via the Intestines
i. Blind-loop syndrome
ii. Overgrowth of bacteria, giardiasis and tapeworm infections
iii. Ileal resection
iv. Crohn’s disease
(d) Inherited (Congenital) Disorders of B12 Deficiency
i. Defect of the intrinsic factor receptor such as in ImerslundGräsback syndrome
ii. Juvenile pernicious anemia—Congenital intrinsic factor (IF) deficiency
iii. Cobalamin mutation (C-G−1 gene)
iv. Deficiency in Transcobalamin (TC)
v. Methylmalonic acidemia, homocystinuria and combined methylmalonic acidemia and homocystinuria [31]
(e) Increased B12 Requirements
i. Hemolytic anemic conditions
ii. HIV infection
(f) Drugs
i. Metformin
ii. Proton pump inhibitors
iii. Prolonged use of histamine receptor 2 (H2) blockers (especially >12 months)
4. Association of Low B12 with Cardiometabolic Risk
4.1. Evidence from Pre-Clinical Studies
Currently, pre-clinical evidence shows that the effect of low B12 on cardiometabolic risk has been
demonstrated mainly using animal models (Table 2). Emerging studies have begun testing some of
these hypotheses on some human cell line and primary cell models. Potential mechanisms underlying
the low B12-cardiometabolic risk associations are being elucidated at the pre-clinical level. In animal
studies, low or deficient B12 level was defined based on plasma levels of B12 in animals fed with
specified diet whereas in in vitro studies, based on the levels of B12 present in the culture media.
The pre-clinical evidence of low B12 that have a role on cardiometabolic risk are provided below.
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4.1.1. Vitamin B12 and Obesity
A study in adult Wistar rats that were fed a B12 restricted diet (control−0.010 mg/kg B12 vs. B12
restricted–0.006 mg/kg B12) during maternal or postnatal period, predicted higher visceral adiposity
and resulted in alteration in the metabolism of lipids in the offspring [35]. Low plasma B12 (277 pg/mL
B12) resulting from B12-restricted diet or a combination of B12- and B9-restricted diet (219 pg/mL B12)
for a period of three months in pre-pregnant Wistar rats resulted in increased body weight compared to
control (1164 pg/mL B12) [35]. B12-deficient rats had increased total body fat whereas B9-deficient rats
presented with elevation in visceral fat mass [35]. Likewise, in female C57 BL/6 mice, severe decrease
in plasma B12 (138 pg/mL), but not moderate (208 pg/mL) (compared to 406 pg/mL control B12) was
reported to induce higher adiposity and altered lipid profile in their offspring [10].
4.1.2. Vitamin B12 and Insulin Resistance
Restriction of maternal B12/folate/methionine (control vs. restricted: B12 (1000.5 pM vs. 198
pM), folate (6.90 nM vs. 4.42 nM), methionine (39.1 µM vs. 30.8 µM)) at the stage of conception in
sheep models, showed increased resistance to insulin and elevated blood pressure in its offspring [36].
In addition, the adult male offspring had higher adiposity and altered functioning of their immunity.
This evidence was explained by the observation of male-specific demethylation of the affected loci,
therefore, providing convincing reasons for the these differences observed in the phenotypes of the
offspring [36]. Finally, the study concluded that the decreased methylation of DNA could be explained
by lower availability of s-adenosyl methionine (SAM), a well-known methyl donor, which is crucial in
epigenetic modulations underlying the development of resistance to insulin [36,37].
4.1.3. Vitamin B12 and Dyslipidemia
Mother Wistar rats with low plasma B12 (277 pg/mL B12 compared to 1164 pg/mL control) produced
offspring which had increased levels of adiposity, triglycerides (TG) and total cholesterol as well as
decreased leptin and adiponectin, compared to control offspring, showing a dysregulated metabolism
of lipids [35]. C57 BL/6 mice with deficient plasma B12 levels at 12 weeks (145 pg/mL vs. 548 pg/mL
control) and 36 weeks (123 pg/mL vs. 522 pg/mL control) had increased plasma TG, cholesterol
and pro-inflammatory markers comprising tumor necrosis factor-alpha (TNFα), interleukin−1 b,
interleukin−6, as well as lower adiponectin concentrations [38]. B12 deficiency inhibited beta oxidation
of fatty acids and lipolysis in hepatic tissues of rat offspring born to B12 deficient mothers (227 pg/mL
B12 vs. 1164 gp/mL control) [39]. However, in these studies, B12 supplementation during parturition
resulted in the restoration of both pathways [39]. In our recent study, targeting the elucidation of the
cellular mechanism induced by low B12 in human adipocyte cell line (Chub-S7 (0.15 nM compared
to 500 nM control)), elevated levels of cholesterol [40] and TG [41] were observed in low B12 cells
compared with controls. This was explained by a reduction in the methylation potential and the
SAM: SAH ratio in low B12 conditions [40]. Validation of the above findings was further endorsed in
primary human adipocyte models, demonstrating that B12-deficient primary human adipocytes had
significantly elevated levels of total cholesterol, tHcy and mRNA expression of key genes that regulate
the biosynthesis cholesterol, as compared to controls [40].
4.1.4. Vitamin B12 and Cardiovascular Diseases
Adult male Sprague–Dawley rat model treated with testosterone enanthate (0.5 mg/100 gm)
and B12 (500 µg/kg) demonstrated significant changes with peripheral cortisol and association with
vascular dysfunction [42]. Another study involving four-weeks simultaneous therapy with 10 mg/kg
folate and 500 µg/kg B12 in Wistar rats, aiming to assess the effect of B12 and folate supplementation
on myocardial infarction (MI) in rats presenting with hyperhomocysteinemia, there was a significant
reduction in the elevated heart rate and blood pressure as well as attenuation of severe cardiac
histopathological alterations [43]. The study suggested that aggravation of MI risk might result from
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hyperhomocysteinemia, however, B12 and/or folate administration may reduce MI risk and tHcy levels,
accounting for reduced harmful consequences associated with hyperhomocysteinemia [43].
Table 2. The effect of low B12 on components of cardiometabolic risk in pre-clinical studies.
Obesity Insulin Resistance Dyslipidemia Cardiovascular Diseases
a. Increased visceral
adiposity in Wistar rats [35].
Increased resistance to
insulin and elevated
blood pressure in sheep
[36,37]
a. Increased adiposity,
TG and total cholesterol
levels in Wistar rat
models [35].
a. Disruption of androgen
testosterone levels
associated with vascular
dysfunction in
Sprague–Dawley rat
model due to low B12 [42]
b. Higher adiposity in
female C57 BL/6 mice [10].
b. Increased plasma TG,
cholesterol and some
pro-inflammatory
markers [38]
b. Reduction in myocardial
infarction (MI) risk and
tHcy levels due to B12 and/
or folate supplementation
in rat models [43]c. Increased body weight in
Wistar rats [35,38]
c. Increased cholesterol
levels in human
adipocyte cell line
(Chub-S7) [40]
d. Higher total body fat in
Wistar rats [35,38]
d. Increased TG in
human adipocyte cell
line (Chub-S7) [41].
4.2. Evidence from Clinical Studies
Most observational and epidemiological evidence on the effects of B12 on metabolic risk are
from an Asian population but there are few studies in Western populations. As previously stated,
the term “low B12” in all clinical evidence reported in this review refers to plasma/serum B12 levels
≤120–300 pmol/L (Table 3).
4.2.1. Vitamin B12 and Obesity
An association between maternal body mass index (BMI) at early stage pregnancy and plasma B12
and/or B9, in a recent cross-sectional study, was observed in obese women compared to women with
normal BMI [44]. Sukumar et al. reported that pregnant women presenting with low B12 at the first
trimester had increased BMI compared with those with normal B12 levels [45]. In India, low maternal
level of B12 was suggestive of contributing to an increased likelihood of developing higher adiposity
and insulin resistance in the offspring [46]. Likewise, the mean B12 concentration was significantly
lesser in children with obesity, compared to healthy volunteers, and was negatively associated with
the severity of obesity [47]. In a recent systematic review of clinical data, although not conclusive,
lower concentrations of B12 were observed in obese individuals compared to overweight and normal
weight individuals [48].
4.2.2. Vitamin B12 and Insulin Resistance
In White Caucasian pregnant women without gestational diabetes mellitus (GDM), an inverse
relationship between B12 level and insulin resistance was reported [49]. Low level of B12 in the
plasma of mothers at early but not late pregnancy, was linked with significant increase in the resistance
to insulin expressed by homeostasis model of insulin resistance (HOMA-IR) in their children [50].
However, there was no relationship established between B9 status in the mothers and insulin resistance
in their children [50]. Similarly, within school children of Nepal, high insulin resistance was observed
as a result of low maternal levels of B12 [51]. In obese adolescents with low or borderline levels of B12,
there was an association between low B12 status and insulin resistance and obesity [52]. In support
of these clinical studies, a study from our group in low B12 pregnant women demonstrated that
altered circulating micro-RNAs derived from adipose tissues could possibly mediate adipogenic and
insulin-resistant phenotypes as a precursor to obesity [41]. In addition, studies from other population
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groups such as women with polycystic ovarian syndrome, adults (males and females) in a primary
care setting, and obese adolescents (males and females) also showed low B12 levels were associated
with higher insulin resistance [29,53,54].
4.2.3. Vitamin B12 and Dyslipidemia
Clinical studies involving three independent cohorts of women; (i) at child-bearing age, (ii) in
early pregnancy, and (iii) at delivery, revealed that low levels of B12 were associated with elevated
levels of low-density lipoprotein (LDL)-cholesterol, total-cholesterol and cholesterol-to-high-density
lipoprotein (HDL) ratio [40]. The study also showed that the women had high prevalence of low B12
(14% in child bearing age, 45% in early pregnancy, 40% during delivery) [40]. Maternal subcutaneous
adipose tissues (ScAT) obtained from mothers with low circulating B12 showed upregulation of
genes involved in the biosynthesis of cholesterol, such as 3-hydroxy−3-methylglutaryl-CoA reductase
(HMGCR), sterol regulatory element binding protein 2 (SREBF2), low-density lipoprotein receptor
(LDLR) and sterol regulatory element binding protein 1 (SREBF1) [40]. These studies implicate that low
B12 status might be causally linked to increased levels of low-density lipoprotein cholesterol (LDL-C),
total cholesterol, cholesterol-to-high-density lipoprotein (HDL) ratio and subsequent insulin resistance.
Further evidence from other studies have shown that babies born to low B12 mothers are ‘thin-fat’,
a term describing phenotypically lean individuals with increased fat accumulation in their bodies as
well as decreased lean mass [46,55]. This may consequently lead to elevated resistance to insulin as
well as increased risk of developing CVD in adulthood [46,55]. In addition, studies in patients with
non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) showed that low
B12 level significantly increased the levels of triglycerides, cholesterol and blood glucose levels in these
patients [56]. A study in adult population from North India showed that low B12 level was observed to
be significantly associated with both low HDL and hyperhomocysteinemia, whereas after controlling
for the confounder tHcy, B12 was found to be associated with all lipid indices including HDL [57].
A negative correlation was also observed between B12 levels and the prevalence of MetS in euthyroid
participants [58].
4.2.4. Vitamin B12 and Cardiovascular Diseases
B12 plays a crucial role in the generation of methionine from tHcy via re-methylation [59].
Therefore, low B12 is associated with an elevation of circulatory tHcy which is known to associate with
the risk of CVD [60]. In Chinese subjects, a study showed a correlation between the highest circulating
levels of B12 and the lowest tHcy levels in patients presenting with CVD [61]. Similarly, in Japanese
subjects, evidence of an inverse relationship was observed between dietary folate (B9) and B6 intake
and the incidence of heart failure mortality in men as well as mortality resulting from stroke, coronary
artery disease (CAD) and total CVD in women [62]. This was similar to the evidence in an American
population study in which therapy for about 7.3 years with a B12–B6–folate combination pill resulted
in a significant decrease in tHcy levels [63]. Other studies suggested that supplementation with 250 µg
B12 and 5 mg folate resulted in 32% reduction of fasting plasma tHcy levels following 12 weeks of
therapy in patients with CAD [64]. A study by Setola et al. [65] demonstrated that folate and B12
treatment in patients with MetS improved resistance to insulin and endothelial dysfunction as well as
decreased tHcy levels, suggesting the beneficial effects of these vitamins on CVD risk factors. Recent
evidence has shown that elevated tHcy and decreased circulatory B12 levels in women, demonstrated
a strong association with higher risk of all-cause and CVD deaths in the elderly population [66].
Meta-analysis of several prospective studies shows reliable evidence of a correlation existing between
plasma tHcy and elevated CVD risk [67]. For instance, in different randomized control trials (RCTs)
involving an established renal disease or CVD, B12 supplementation using a dosage range of 0.4–1.0
mg B12 per day accounted for a significant reduction in the risk of developing stroke [67]. Meanwhile,
studies have proposed that hyperhomocysteinemia and cardiovascular risk in patients may precede
the development of end-stage renal disease (ESRD), chronic kidney disease (CKD) and dialysis [68–70].
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Although CKD patients demonstrate an impairment in tissue uptake of B12 resulting in functional
deficiency [71], the current evidence remains unclear to consider altered B12, folate and elevated tHcy
levels as markers for CVD and cardiovascular mortality risk in ESRD and CKD individuals [72].
Table 3. The effect of low B12 on components of cardiometabolic risk in clinical studies.
Obesity Insulin Resistance Dyslipidemia Cardiovascular Diseases
a. Low B12 (<150
pmol/L) was associated
with increased adiposity
with higher T2D risk in
pregnant women [46]
b. Low B12 (<180 pmol/L
[49]) was associated with
increased resistance to
insulin in White
Caucasian pregnant
women without GDM.
a. Low B12 (<148
pmol/L) was associated
with elevated levels of
LDL-cholesterol,
total-cholesterol and
cholesterol-to-HDL ratio
in pregnant and
non-pregnant women at
childbearing age [40]
a. B12 was negatively
correlated with tHcy levels
in Chinese-CVD patients ≥
65 years of age (median low
B12 = 4.19 pmol/L) [61].
b. Low B12 (median−203
pmol/L [44] and <148
pmol/L [48]) levels were
associated with increased
BMI in maternal and
general and/or clinal
populations respectively
b. Prediction of higher
risk of resistance to
insulin in children born
to low B12 (<150 pmol/L
[46], 148 pmol/L [50])
mothers
b. Low B12 (≤220 pg/mL)
was associated with both
low HDL and
hyperhomocysteinemia
in North Indian
population [57]
b. Low B12 (<148 pmol/L)
and high tHcy levels were
associated with higher risk
of all-cause and CVD deaths
in aged women [66]
c. Low B12 (102–208
pmol/L interquartile
range) was associated
with obesity in children
compared to healthy
volunteers [47].
c. Low B12 (≤150 pmol/L
[29], <148 pmol/L [52],
<200 pg/mL [53], <178
pg/mL [54]) levels were
associated with increased
IR in adult patients,
polycystic ovarian
syndrome women and
obese adolescents
c. B12 negatively
correlated with markers
of MetS such as low HDL
and high TG levels in
erythroid patients (Low
B12 range 180–301
pmol/L) [58]
c. B12 supplementation
reduced the risk of stroke in
patients with CVD and/or
renal disease [67].
5. Molecular Mechanisms Regulating Low B12 and Lipogenesis
Environmental factors such as nutrition may affect lipid metabolism by targeting at the
transcriptional level, thereby, regulating the expression of genes and subsequently the phenotype
without altering the sequence of nucleotides by the process of epigenetics [73]. B12 plays a crucial role
in humans by serving as a cofactor in the reaction pathways essential for maturation and preservation
of cells [74,75]. In the cytosol, B12 is a cofactor for methionine synthase (MS) (Figure 2), which is
actively involved in the biosynthesis of methionine via re-methylation of tHcy and in turn generation of
s-adenosyl methionine (SAM), a potent donor of methyl groups for methylation of several biochemical
processes. Currently, the well-known markers of epigenetic mechanisms that regulate the metabolism
of lipids and resistance to insulin are DNA methylation, microRNAs, chromatin remodeling as well
as modification of histones [76,77]. B12 acting as a co-enzyme for a source of methyl groups (SAM),
regulates these epigenetic mechanisms and several transcriptional as well as post-translational factors
involved in the process of de novo lipogenesis. In the mitochondrial based propionate metabolism
pathway, B12 serves as a cofactor in the conversion of methyl malonyl-CoA to succinyl-CoA by methyl
malonyl-CoA mutase (MCM) (Figure 2) [78]. Succinyl-CoA is utilized as substrate in the Krebs cycle
for ATP synthesis essential for the sustenance of cellular metabolisms (reviewed by [79]) and utilized
for hemoglobin synthesis in red blood cell production. Low B12 levels, therefore, results in a reversible
increase in methyl malonyl-CoA leading to accumulation of MMA. MMA, in turn, acts as a potent
inhibitor of the rate limiting enzyme carnitine palmitoyl transferase 1 (CPT1), critical for the breakdown
of long chain fatty acids in the beta oxidation pathway. This inhibition of CPT1 may build up fatty
acids and TGs (reviewed by [80]) accounting for higher lipogenesis and insulin resistance [81] which
might result in dyslipidemia.
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6. Epigenetic Mechanisms Underlying Low B12 Levels in Lipid Metabolism
There is currently, emerging evidence suggesting that abnormalities associated with one-carbon
metabolites due to low B12, might possibly exert their modulations through epigenetic mechanisms.
Some preliminary findings have indicated that induction of alterations in normal methylation of DNA
is due to changes in the levels of one-carbon metabolites. However, it was suggested that in order to
elucidate the molecular mechanism underlying these effects, there is a need for future studies to target
combinations of gene expression assays with epigenetic studies [79]. Studies in animals are likely to be
more informative as clear elucidation of molecular mechanisms in humans might be difficult due to
tissue-specificity of the epigenetic phenomena [79].
6.1. DNA Methylation and Regulation of Lipid Metabolism through Low B12
Methylation generally involves the process of transferring a methyl group to substrates such as
enzymes, proteins, amino acids and DNA in diverse cells and tissues [82]. In the process, guanine
is normally bound with 5-methylcytosine following its development from cytosine [83]. Usually,
hypermethylation of global DNA and 5′-cytosine-phosphate-guanine−3′ (CpG) islands located within
the promoters of genes involved in lipid synthesis, accounts for the stability of the genome and silencing
of the lipogenic genes, respectively [84]. This is greatly dependent on the availability and sufficiency of
SAM synthesized with the aid of methyl donors such as B12 and folate [76]. Low B12 independently
impairs the MS action [85] affecting SAM/SAH ratio which is a principal determinant of the methylation
potential of cellular DNA, thereby inducing dysregulation of gene expressions [86,87]. Demethylation
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associated with DNA of the genome, persists as one of the earliest evidences of epigenetic modifications
triggered by diets deficient in methyl donors, contributing to hepatocarcinogenesis in animals [88].
A study in zebrafish showed that micronutrient-deficient diet (without 1-carbon nutrients B12,
B9, B6, methionine and choline supplementation compared to control), fed to parents affected the
hepatic methylation of DNA and gene expression of lipogenesis leading to lipid accumulation in the
F1 offspring [87]. High global methylation of DNA and promoter region methylation of lipid genes
are critical to the maintenance of normal physiology of metabolism [89,90] by ensuring stability of
the genome and silencing of abnormal lipogenic genes [84]. A study in an adipocyte model showed
that hypomethylation in promoter regions led to higher expressions of LDLR and SREBF1 genes and
cholesterol biosynthesis in low B12 (0.15 nM B12 media compared to 500 nM control) [40]. Increased
genome incorporation with uracil subsequent to hypomethylation was observed in B12-deficient
rats (50 µg/kg B12 fed to Sprague–Dawley rats) [91], whereas fatty acid supplementation in low B12
conditions could not restore global methylation [92]. Evidence of hypomethylation, as seen in low
B12, was observed in the CpG sites of some liver-derived genes involved in the pathogenesis of T2D
due to low folate levels [93]. Methyl donor supplementation in rat obesogenic models ameliorated
hypomethylation near the promoter of genes such as acylglycerol−3-phosphate-O-acyltransferases 3
(AGPAT3), SREBF2 and ESR1 (estrogen receptor−1) resulting in the reversion of higher fatty acid, TG and
cholesterol accumulation in the liver [94]. These studies thus implicate that methyl donor deficiency
compromises methylation capacity, resulting in the dysregulation of lipid metabolism [87,95,96] which
can be reversed by supplementation of methyl donors.
6.2. MicroRNAs (miRNAs) and Regulation of Lipid Metabolism through Low B12
MicroRNAs (miRNAs), formerly termed as small temporal RNAs (stRNAs), are the class of
small RNAs comprising 21–25 nucleotides of single-stranded RNA which are highly conserved and
engaged in regulating the expression of genes at the transcriptional and post-translational levels [97].
MiRNAs physiologically express diversified patterns and engage in the regulation of certain genes
underlying the metabolism of lipids and inflammation [98,99]. MiRNAs are proposed to be engaged in
the modulation of adipocyte differentiation accounting for development of insulin resistance, T2D and
dyslipidemia [100,101]. Genes regulating hepatic metabolism of fatty acids and/or insulin signaling may
be repressed by some miRNAs regulating the levels of HDL, TG and insulin [102]. About 100 different
miRNAs are expressed differentially in cases of NASH in humans [103] and alterations in miRNA-29c,
miRNA-34a, miRNA-200b and miRNA-155 are due to methyl-donor deficiencies [104]. In humans,
miRNA-122 is largely expressed in hepatocytes but under expressed in NASH [104] and therefore
is proposed to be the potential target for treatment of dyslipidemia [105] and high cholesterol [106].
Using adipocyte models, our group reported that twelve different adipocyte-derived miRNAs targeting
peroxisome proliferator-activated receptor gamma (PPARγ) (miRNA-31, miRNA-130b and miRNA-23a),
adipocyte differentiation (miRNA-143, miRNA-145, miRNA-146a, miRNA-125b, miRNA-222 and
miRNA-221), CCAAT/enhancer-binding protein alpha (miRNA-31) and pathways of insulin resistance
(miRNA-107 and miRNA-103a) were significantly altered due to low B12, thereby modulating adipocyte
differentiation and physiology [41]. In addition, B12 levels were positively associated with seven
different circulating miRNAs (miRNA-27b, miRNA-130, miRNA-103a, miRNA-107, miRNA-125b,
miRNA-23a, miRNA-221 and miRNA-222). Of these, four (miRNA-107, miRNA-27b, miRNA-23a and
miRNA103a) were inversely and independently associated with maternal BMI, similar to low B12 after
adjusting for likely confounders (such as age, parity, smoking, supplement use, glucose and insulin).
The reduction in effect size between B12 and BMI on additional adjustment for these four miRNAs,
highlights that some of the negative effects of B12 on BMI may be mediated by these miRNAs [41].
6.3. Modifications of Histones and Regulation of Lipid Metabolism through Low B12
The mechanistic effect of B12 on hepatic lipid metabolism regulation via modulation of histones
is primitive. However, mechanisms including methylation, acetylation, phosphorylation as well as
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ubiquitylation are proposed to be involved in ubiquitylation modification of histones that contribute
to lipid metabolism regulation in the liver. The most intensively understood mechanism directly
involved in dysregulation of hepatic lipid metabolism is histone acetylation which is normally catalyzed
by histone acetyltransferases (HATS) and histone deacetylases (HDACs). In female C57 BL/6 mice,
chronic deficiency of B12 (580 pmol/L B12 compared to 2331 pmol/L control) showed a dysregulated
histone-modifying enzyme expression in the brain and abnormal behavioral anomalies [107]. Recent
evidence from pilot data indicated that low folate level in the liver was associated with higher levels
of methylation in H3 K4 [108]. Reduced methylation of histone has also been shown in liver X
receptor-alpha (LXRα) in rats, following consumption of a high-fat diet after the third generation in
rats [109]. Histones such as H3 lysine 4 (H3 K4) and H3 lysine 9 (H2 K9) are known to be subjected to
regulation by methylation of the histones in association with DNA methylation [110]. Evidence of
deficiency in the methyl donor choline in C57 BL/6 mice at the 12th–17th day of gestation resulted in
alterations in the methylation of histone H3, whereas choline after undergoing conversion to betaine,
enhanced re-methylation to tHcy [111]. Convincing evidence shows the link between NAFLD [73],
resistance to insulin and obesity with modification of histone such as demethylation of H3 at lys9 [112].
Conditions of hyperlipidemia and obesity were observed in mouse models following the functional
loss of Jhdm2 a, the H3 K9-specific demethylase, which implies that the status of methylation of H3 K9
is very essential and may tend to regulate the expression of metabolic genes [113]. Further studies
are recommended to determine the exact role of B12 on the metabolism of lipids via modulation
of histones.
7. Impact of One-Carbon Micronutrient Supplementation on Lipid Metabolism
In recent times, although agents that potentially resolve insulin resistance appear promising,
the general therapy for correcting dysregulation of lipogenesis has not been established. However,
current treatment may be reliant on alterations in lifestyle such as diet, weight reduction and/or
exercise [114]. It is generally suggested that interventions involving fortification of foods,
supplementation with B12 during preconception period and provision of adequate education could
collectively be the most effective ways to enhance improvement in the levels of B12 in infants as well
as mothers [115]. Supplementing with a diet rich in one-carbon nutrients such as vitamin B6, B9 and
B12, is the principal way to significantly influence methylation of DNA because of their contribution
to the synthesis of SAM. A similar micronutrient, betaine, obtained from food functions as a methyl
donor and has been identified as a potent alleviator of fatty liver. Betaine was shown to facilitate
the export of triglycerides from the liver as a way of attenuating steatosis, especially in cases of
NAFLD [116]. Post-supplementation with only B12 was associated with significant alteration in the
methylation of DNA in which 589 CpGs demonstrated differential methylation in addition to 2892
regions. Supplementation with both B12 and folate resulted in differential methylation of 169 CpGs
and 3241 regions, thereby influencing the expression of genes associated with T2D [117]. Evidence
of higher percentage of transmethylation to methionine and reduced transculturation to cysteine
were observed as a result of supplementation with both B12 and milk protein compared with only
milk supplementation in women. Therefore, among Indian women presenting with low B12 in early
pregnancy, supplementation with B12 and energy-protein balance plays a crucial role in enhancing
the optimum function of the methionine cycle especially at the third trimester of pregnancy [118].
Similarly, B12, folate, choline and betaine-rich methyl donor supplements were used to regress the
accumulation of fats in the liver induced by high-fat-sucrose probably by changing the levels of
methylation of CpG areas in the promotor regions of SREBF2, estrogen receptor 1 (ESR1) and/or
acylglycerol−3-Oacyltransferase−3 (AGPAT3) [96]. Hypermethylation of DNA in fatty acid synthase
(FAS) gene expression was estimated after supplementation with methyl donors that apparently boosted
the retrogression of NAFLD-induced by high fat diet [94]. Normalization of histochemical indices in
hepatic lobules was achieved in an animal-model study where the accumulation of lipids towards
the center of hepatic lobules was brought under control subsequent to treatment with methionine
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in combination with vitamin B12 rather than B15 [119]. Finally, oral B12 supplementation during
pregnancy resulted in higher plasma B12 levels in infants and reduction in MMA and tHcy levels [120].
8. Conclusions and Prospects
In summary, the global incidence of metabolic disorders is increasing with advancement in
urbanization in addition to several environmental and genetic factors. The pathogenesis of MetS,
T2D and CVD have been associated with deficiencies in micronutrients. The effect of low B12 on the
pathogenesis of several metabolic disorders such as obesity, insulin resistance, T2D and CVD, has been
studied at the pre-clinical and clinical levels. Clinically, low B12 status in children, adolescents and
pregnant mothers was associated with higher adiposity and lipids, as well as increased risk of insulin
resistance, T2D and CVD. Babies born to low B12 mothers via adverse maternal programming seem
to have a high accumulation of adiposity and insulin levels at birth which may predispose them to
a higher risk of developing cardiometabolic disorders in later life. This review provides compelling
evidence that the regulation of lipids and increased adiposity are associated with low B12 via epigenetic
mechanisms. Future studies with a critical emphasis to establish causality by understanding the
functional relevance of these epigenetic changes induced by low B12 are required.
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AGPAT3 Acylglycerol−3-phosphate O-acyltransferases 3
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C
CAD Coronary artery disease
CHD Coronary heart disease
CKD Chronic kidney disease
CpG 5′cytosine-phosphate-guanine-3′
CPT1α Carnitine palmitoyl transferase I alpha
CVD Cardiovascular diseases
D
DAG Diacylglycerol
DGAT 1&2 Diacylglycerol acyltransferase 1&2
DKA Diabetic keto acidosis
DM Diabetes mellitus
DMB 5, 6-dimethylbenzimidazole
DNMTs DNA methyl transferases
E
ESRD End-stage renal disease
ESR1 Estrogen receptor 1
ETC Electron transport chain
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F
FAO Fatty acid oxidation
FAS Fatty acid synthase
FFA Free fatty acids
G
GDM Gestational diabetes mellitus
GIT Gastrointestinal tract
GPAT Glycerol-3-phosphate acyltransferase
H
HATS Histone acetyltransferases
HC Haptocorrin
HDACs Histone deacetylases
HDL-C High-density lipoprotein cholesterol
HFD High fat diet
tHcy total homocysteine
HMGCR 3-hydroxy-3-methylglutaryl-CoA reductase
HMGCS 3-hydroxy-3-methylglutaryl-CoA synthase
HoloTC Holotranscobalamin
HOMA-IR Homeostasis model of insulin resistance
I
IDF International Diabetes Federation
IF Intrinsic factor
IR Insulin resistance
L
LCFAs Long-chain fatty acids
LDL-C Low-density lipoprotein cholesterol
LDLR Low-density lipoprotein receptor
LXR-α Liver X receptor alpha
M
MCM Methyl malonyl CoA mutase
MeCbl Methyl-cobalamin
MetS Metabolic syndrome
MI Myocardial infarction
MMA Methyl malonic acid
MS Methionine synthase
MP Methylation potential
miRNAs MicroRNAs
N
NAFLD Non-alcoholic fatty liver disease
NASH Non-alcoholic steatohepatitis
P
PPAR-γ Peroxisome proliferator-activated receptor gamma
S
SAM S-adenosyl methionine
SAH S- adenosyl homocysteine
ScAT Subcutaneous adipose tissues
SREBF1&2 Sterol regulatory element binding protein 1 and 2
stRNAs Small temporal RNAs
T
TCA Tricarboxylic acid
TC Transcobalamin
TCR or TCbIR Transcobalamin receptor
T2D Type 2 diabetes mellitus
TG Triglyceride/Triacylglycerol
TNFα Tumor necrosis factor-alpha
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VLDL Very low-density lipoprotein
W
WHO World Health Organization
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